Consort Medical plc (LON:CSRT) has received an average recommendation of “Buy” from the seven analysts that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is GBX 1,200.80 ($16.16).
Several equities research analysts have recently weighed in on CSRT shares. N+1 Singer cut Consort Medical to a “hold” rating in a research note on Tuesday. Stifel Nicolaus reissued a “buy” rating and issued a GBX 1,250 ($16.82) price target on shares of Consort Medical in a research note on Thursday, November 9th. Numis Securities increased their price target on Consort Medical from GBX 1,084 ($14.59) to GBX 1,144 ($15.40) and gave the company a “hold” rating in a research note on Wednesday. Finally, Shore Capital restated a “buy” rating on shares of Consort Medical in a research report on Tuesday.
Shares of Consort Medical (LON:CSRT) traded up GBX 10 ($0.13) on Monday, reaching GBX 1,159 ($15.60). The company’s stock had a trading volume of 27,404 shares, compared to its average volume of 22,318. Consort Medical has a fifty-two week low of GBX 960 ($12.92) and a fifty-two week high of GBX 1,180 ($15.88).
About Consort Medical
Consort Medical PLC is a contract development and manufacturing organization (CDMO). The Company’s principal activities include designing, development and manufacture of medical drug delivery devices and services for the pharmaceutical industry. The Company operates through two segments: Bespak and Aesica.
Receive News & Ratings for Consort Medical plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical plc and related companies with MarketBeat.com's FREE daily email newsletter.